Navigation Links
Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration
Date:11/9/2009

BEND, Oregon, November 9 /PRNewswire/ -- Bend Research Inc., a company with more than 30 years of experience in applying innovative pharmaceutical technologies to help clients solve their most difficult scientific and technical problems, announced today that it has entered into a collaboration with Vertex Pharmaceuticals Incorporated, a global biotechnology company headquartered in Cambridge, MA.

Through this new collaboration, Vertex will utilize Bend's formulation development and manufacturing services for specific projects and clinical trials, with the goals of both enhancing the delivery of Vertex compounds and supporting the progression of certain Vertex product candidates through clinical development.

The collaboration between Bend Research and Vertex is designed to leverage the fundamental scientific capabilities of each company to solve formulation and process-development challenges and to produce commercial drug products that are optimized for therapeutic benefit.

"It's a great opportunity for both companies," Bend Research CEO Rod Ray explained. "We are excited to be working with Vertex. We share their commitment to delivering breakthrough therapies based on cutting-edge science. Having two great teams working side by side is a powerful combination - we look forward to a long and fruitful relationship."

Vertex's Executive Vice President of Global Research and Development and Chief Scientific Officer, Peter Mueller, added, "Our collaboration with Bend Research exemplifies Vertex's commitment to the treatment of serious diseases through cutting-edge science and innovative technologies. We believe Bend's technologies and expertise will provide Vertex with important scientific capabilities that will support our drug development efforts."

Bend Research is making its multidisciplinary team of scientists and engineers available to companies for solving tough formulation and development problems. Bend Research prides itself in offering fast, innovative solutions.

Since late 2008, Bend Research has been rapidly expanding its line-up of industrial partners. Customers that have benefitted from Bend Research's proprietary technology and unique formulation expertise include some two dozen major pharmaceutical companies, mid-size pharmas, and biotech companies around the globe.

About Bend Research Inc.

Bend Research has more than 30 years of experience in helping clients solve their most difficult scientific and technical problems. This success is based on the company's ability to develop, advance and commercialize pharmaceutical technologies. The firm develops innovative drug-delivery solutions from a solid base of fundamental understanding. Bend Research provides formulation and dosage-form support, assists in process development and optimization, manufactures clinical trial quantities of drug candidates in its cGMP facility, and advances promising drug candidates from conception through to commercialization.

The company's flexible, client-focused business model and collaborative approach to working with its customers enable long-term alliances with clients focused on value creation.

Bend Research has more than 140 employees based in three state-of-the-art facilities in Bend, Oregon, USA.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small-molecule drugs for serious diseases. The company's strategy is to commercialize products independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.

    Contact:

    Dana Settell
    Bend Research Inc.
    64550 Research Road
    Bend, OR 97701

    Phone: +1(541)-382-4100
    Fax: +1(541)-382-2713
    E-mail: settell@bendres.com

SOURCE Bend Research Inc.


'/>"/>
SOURCE Bend Research Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017   The Accreditation Council for Medical ... in the pharmaceutical industry has appointed Dr. ... newly formed scientific advisory board. Dr. Chin will ... first ever medical affairs think tank within the ... the ACMA, please visit  www.medicalaffairsspecialist.org .  Connect ...
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research and ... (IPF) Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with ... Corporation, Merck & Co., Inc., Biogen and Sanofi are involved in the ... candidates, of which one is in Phase III stage, 15 are in ...
(Date:3/24/2017)... , March 24, 2017 Today ... Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. ... Inc. (NASDAQ: SSH ). These companies are part ... prior gains on Thursday, March 23 rd , 2017, with ... while shares of health care companies in the S&P 500 ...
Breaking Medicine Technology:
(Date:3/24/2017)... , ... March 24, 2017 , ... The Radiology ... Quest Awards . The annual awards, now in their 12th year, are among the ... the winners. , In 2016, the awards were retooled to recognize achievements in both ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents her Sacred ... 2017. This sacred and spiritual journey during the Summer Solstice will also ...
(Date:3/24/2017)... ... 2017 , ... The law firm of Enea, Scanlan & Sirignano, LLP, ... resident Lauren C. Enea has joined the firm as an associate attorney. Ms. Enea, ... in elder law, Medicaid planning and applications, and Wills, Trusts and Estates. Samantha ...
(Date:3/24/2017)... ... 2017 , ... “Finding Christ Through Social Media: Year One ... the writer’s path toward true communion with God. “Finding Christ Through Social Media: ... creation of published author Lea Michelle Johnson, a follower of Christ, wife and ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... In 2016 ... now estimates that there could be four million Zika-related cases in the Americas within ... with numbers of US cases reported per year skyrocketing to an estimated 329,000. Yet, ...
Breaking Medicine News(10 mins):